Dr. Daniel A. Pollyea, MD
Hematology & Oncology (Hematology & Oncology Physician)
12605 E 16th Ave
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Chicago, Pritzker School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 102
Licensed in Illinois since 2006, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Chicago, Pritzker School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CO license DR-50375 (first issued 2011; active) · CA license A98326 -
Internal Medicine Physician
IL license 036-115327 (first issued 2006; inactive)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Colorado Hospital Authority Aurora, CO
- Uchealth Highlands Ranch Hospital Highlands Ranch, CO
- Children's Hospital Colorado Aurora, CO
Medical groups
- University Physicians Incorporated (3,215 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 102
- Services billed
- 381
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 255 | 63 |
| Established patient office or other outpatient visit, 30-39 minutes | 82 | 39 |
| Established patient office or other outpatient visit, 40-54 minutes | 44 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Aurora, CO | 49 |
| Venclexta (venetoclax) | 42 |
| Tasigna (nilotinib hcl) | 40 |
| Sprycel (dasatinib) | 28 |
| Tibsovo (ivosidenib) | 27 |
| Ondansetron Hcl Other prescribers in Aurora, CO | 22 |
| Imatinib Mesylate | 21 |
| Inqovi (decitabine/cedazuridine) | 20 |
| Levofloxacin Other prescribers in Aurora, CO | 17 |
| Fluconazole Other prescribers in Aurora, CO | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 42 payments worth $31,118 in total to this clinician.
| Servier Pharmaceuticals LLC | $6,054 |
|---|---|
| AbbVie Inc. | $4,993 |
| Geron Corporation | $4,224 |
| Syndax Pharmaceuticals, Inc. | $3,777 |
| E.r. Squibb & Sons, L.l.c. | $2,865 |
| Astellas Pharma US Inc | $2,722 |
| Astellas Pharma Global Development | $2,652 |
| Genentech USA, Inc. | $1,847 |
| Consulting Fee | $22,627 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $3,656 |
| Travel and Lodging | $2,842 |
| Food and Beverage | $1,035 |
| Honoraria | $685 |
| Speaking at a medical education program | $272 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Servier Pharmaceuticals LLC Sep 19, 2025 | Consulting Fee Tibsovo · Oncology | $4,080 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $3,200 |
| E.r. Squibb & Sons, L.l.c. Nov 24, 2025 | Consulting Fee | $2,865 |
| Geron Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) IMETELSTAT · HEMATOLOGY | $2,681 |
| Astellas Pharma Global Development Apr 30, 2025 | Consulting Fee Xospata · Oncology | $2,652 |
| Astellas Pharma US Inc Jan 22, 2025 | Consulting Fee Xospata · Oncology | $2,600 |
| AbbVie Inc. Jun 11, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $2,250 |
| AbbVie Inc. Sep 3, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,875 |
| Genentech USA, Inc. Dec 6, 2025 | Consulting Fee Venclexta · BioOncology | $1,640 |
| Geron Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) IMETELSTAT · HEMATOLOGY | $975 |
All 26 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Dec 6, 2025 | Consulting Fee Venclexta · BioOncology | $1,640 |
| Geron Corporation Dec 5, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to ORLANDO, FL | $341 |
| E.r. Squibb & Sons, L.l.c. Nov 24, 2025 | Consulting Fee | $2,865 |
| Taiho Oncology, Inc. Nov 15, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $36.44 |
| Taiho Oncology, Inc. Oct 31, 2025 | Speaking at a medical education program | $272 |
| Taiho Oncology, Inc. Oct 31, 2025 | Travel and Lodging travel to San Diego, CA | $23.32 |
| Servier Pharmaceuticals LLC Oct 2, 2025 | Consulting Fee Tibsovo · Oncology | $680 |
| Rigel Pharmaceuticals, Inc. Sep 30, 2025 | Honoraria Rezlidhia · Acute Myeloid Leukemia | $685 |
| Servier Pharmaceuticals LLC Sep 19, 2025 | Consulting Fee Tibsovo · Oncology | $4,080 |
| Servier Pharmaceuticals LLC Sep 19, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $615 |
| Servier Pharmaceuticals LLC Sep 19, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $500 |
| Servier Pharmaceuticals LLC Sep 19, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $113 |
| AbbVie Inc. Sep 3, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,875 |
| AbbVie Inc. Sep 3, 2025 | Travel and Lodging VENCLEXTA · ONCOLOGY · travel to BERGAMO, Italy · in-kind | $593 |
| AbbVie Inc. Sep 3, 2025 | Travel and Lodging VENCLEXTA · ONCOLOGY · travel to BERGAMO, Italy · in-kind | $47.57 |
| AstraZeneca Pharmaceuticals LP Aug 27, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $97.31 |
| Taiho Oncology, Inc. Aug 27, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $57.82 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $3,200 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind | $377 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind | $41.00 |
| Geron Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) IMETELSTAT · HEMATOLOGY | $2,681 |
| Geron Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) IMETELSTAT · HEMATOLOGY | $975 |
| Genmab U.S., Inc. Jun 20, 2025 | Consulting Fee Epkinly · Oncology | $785 |
| AbbVie Inc. Jun 11, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $2,250 |
| Astellas Pharma Global Development Apr 30, 2025 | Consulting Fee Xospata · Oncology | $2,652 |
| Astellas Pharma US Inc Jan 22, 2025 | Consulting Fee Xospata · Oncology | $2,600 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $144,419 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Taiho Oncology, Inc. - A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS).
Taiho Oncology, Inc. - CC-486 (Onureg) and Venetoclax in Previously Untreated Elderly Patients with Acute Myeloid Leukemia
Celgene Corporation - A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Ac…
Amgen Inc. - A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc. · Recruiting · NCT04988555
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.